Phase 3Completed
Glizigen-Viudid-External Anogenital Warts in Children and Adolescents
Efficacy of Glizigen-Viudid in the Treatment of External Anogenital Warts in Children and Adolescents.
- Sponsor
- Catalysis SL (Industry)
- Enrollment
- 76 enrolled
- Conditions
- External Anogenital Warts
- Interventions
- Glizigen + Viusid; Placebo
- Ages
- children, adults
- Registry
- NCT01111344
Full record on ClinicalTrials.gov
From the registry
The purpose of the study is to assess the efficacy of Glizigen and Viusid administration in the treatment of external anogenital warts in children and adolescents. The duration of this double-blind placebo controlled phase 3 clinical trial will be 12 weeks. The estimated number of persons to be recruited and randomized for the study is 76. Variables to be assessed will be: time to disappearance of lesions, reduction of the number of lesions and change in the aspect of lesions.
Primary outcomes
- Time to lesion regression
History
Last registry update
Primary completion
Started
Registered